Skip to main
SXTP

SXTP Stock Forecast & Price Target

SXTP Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

60 Degrees is showing positive clinical progress in their development of tafenoquine for Babesiosis, with all patients in the expanded-access study being cured and enrollment underway for the chronic Babesiosis Phase II study. The company also saw strong growth in ARAKODA sales in FY25 and raised additional funding through ATM sales. With a pipeline of promising products and a potentially underserved market for infectious disease treatments, there is potential for the stock to see significant upside in the near term, although risks such as regulatory approvals and potential dilution from future financings should be considered.

Bears say

60 Degrees is struggling to generate significant revenue with a slow quarter in FY25, while its growth potential from a recent partnership with Runway Health and its strong pipeline of products targeting various infectious diseases may lead to growth potential in the future. Their focus on expanding ARAKODA's access and a new phase 2 Babesiosis study could be positive catalysts, but it is still important to monitor the company's financial performance and competition in the market before considering investing.

SXTP has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of 60 Degrees Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About 60 Degrees Pharmaceuticals Inc (SXTP) Forecast

Analysts have given SXTP a Strong Buy based on their latest research and market trends.

According to 2 analysts, SXTP has a Strong Buy consensus rating as of May 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

60 Degrees Pharmaceuticals Inc (SXTP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.